Summary of Significant Accounting Policies - Additional Information (Detail) $ / shares in Units, € in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2017 USD ($) Distributor	Sep. 30, 2017 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Dec. 31, 2016 USD ($) Distributor	Sep. 30, 2016 USD ($)	Jun. 30, 2016 USD ($)	Mar. 31, 2016 USD ($)	Dec. 31, 2017 USD ($) Distributor $ / shares	Dec. 31, 2017 EUR (€) Distributor	Dec. 31, 2016 USD ($) Distributor	Dec. 31, 2015 USD ($)	Jan. 01, 2018 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Net (loss) income	$ (32,784,000)	$ (32,886,000)	$ (35,339,000)	$ (16,324,000)	$ 53,976,000	$ 126,520,000	$ (29,959,000)	$ (24,873,000)	$ (117,333,000)		$ 125,664,000	$ (368,445,000)
Net revenue - commercial product sales	1,200,000								9,192,000		1,895,000
Net deferred revenue	$ 3,038,000				3,419,000				$ 3,038,000		3,419,000
Number of wholesale distributors | Distributor									3	3
Percentage of product shipments to wholesale distributors									89.00%	89.00%
Deferred revenue from sale of raw insulin									$ 0		1,700,000
Cash discount as incentive for prompt payment	2.00%								2.00%
Revenue - other									$ 2,303,000		$ 898,000
Maturity period of cash equivalents									90 days or less at the time of purchase	90 days or less at the time of purchase	90 days from the date of purchase
Allowance for doubtful accounts	$ 0				$ 0				$ 0		$ 0
Number of wholesale distributors accounted for gross accounts receivable | Distributor	3				3				3		3
Percentage of accounts receivable from major wholesale distributors	93.00%				95.00%				93.00%		95.00%
Inventory charge									$ 3,000,000		$ 0	39,300,000
Percentage of credit exchange receivable									65.00%	65.00%
Estimated amounts receivable under program	$ 0				$ 200,000				$ 0		200,000	700,000
Prepaid expenses and other current assets	3,010,000				4,364,000				$ 3,010,000		4,364,000
Long-lived assets anticipated sale in year									1 year	1 year
Asset impairment charge									$ 200,000		1,300,000	140,600,000
Purchase commitment obligation	109,300,000								$ 109,300,000			116,200,000
Long term purchase commitment | €										€ 90.3
Revenue recognition, milestone method, number of milestone									13	13
Liability for uncertainty in income taxes	0								$ 0
Outstanding warrants					7,400,000						7,400,000
Interest cost capitalized									$ 0		0	100,000
Lessee, term of contract									12 months	12 months
Restricted cash balances	4,400,000				0				$ 4,400,000		0
Accumulated Deficit
Summary Of Significant Accounting Policies [Line Items]
Net (loss) income									(117,333,000)		125,664,000	(368,445,000)
Accumulated Deficit | Subsequent Event
Summary Of Significant Accounting Policies [Line Items]
Cumulative effect adjustments on accumulated deficit													$ 1,700,000
Sanofi-Aventis Deutschland GmbH
Summary Of Significant Accounting Policies [Line Items]
Long term purchase commitment												$ 50,000,000
Deerfield | Milestone Rights Liability | Senior convertible notes due December 31, 2019
Summary Of Significant Accounting Policies [Line Items]
Long term liability	8,900,000				8,900,000				8,900,000		8,900,000
Certificates of Deposit
Summary Of Significant Accounting Policies [Line Items]
Prepaid expenses and other current assets	400,000				400,000				400,000		400,000
Intellectual property
Summary Of Significant Accounting Policies [Line Items]
Revenue - other			$ 600,000						600,000
Third party logistics
Summary Of Significant Accounting Policies [Line Items]
Net deferred revenue	$ 1,500,000				$ 800,000				1,500,000		800,000
Inventory in Distribution Channel
Summary Of Significant Accounting Policies [Line Items]
Net (loss) income									$ 1,200,000
Basic and diluted net income (loss) per share | $ / shares									$ 0.01
AFREZZA product sales
Summary Of Significant Accounting Policies [Line Items]
Product sales revenue gross to net adjustments									$ 3,400,000		$ 800,000
Product sales revenue gross to net adjustments percentage									27.00%	27.00%	30.00%
AFREZZA product sales | Sales through Specialty Pharmacies
Summary Of Significant Accounting Policies [Line Items]
Net revenue - commercial product sales									$ 500,000
Bulk insulin sales
Summary Of Significant Accounting Policies [Line Items]
Revenue - other									$ 1,700,000
Minimum | AFREZZA product sales
Summary Of Significant Accounting Policies [Line Items]
Sales return right following product expiration in months									6 months	6 months
Maximum | AFREZZA product sales
Summary Of Significant Accounting Policies [Line Items]
Sales return right following product expiration in months									12 months	12 months